---
title: Public trust and perception of pharmaceutical companies
videoId: Z_LhPMhkEdw
---

From: [[lexfridman]] <br/> 

The relationship between the public and pharmaceutical companies has long been complex, shaped by factors including historical events, media portrayal, and recent global health crises. This article explores the state of public trust in pharmaceutical companies, with a focus on the broader themes discussed in a conversation involving Albert Bourla, CEO of Pfizer, which reflects on the challenges and avenues for building trust.

## Evolving Public Trust

Pharmaceutical companies have historically faced significant challenges in maintaining public trust. The industry's reputation reached its "lowest [point]" in the last decade, largely due to behaviors within the industry that required significant change according to Albert Bourla <a class="yt-timestamp" data-t="00:20:51">[00:20:51]</a>. However, the COVID-19 pandemic presented an opportunity for companies like Pfizer to demonstrate their capabilities and regain some public confidence through [[covid19_vaccine_development_and_public_perception | COVID-19 vaccine development]].

> "The development of the COVID-19 vaccines is one of the greatest accomplishments of science and recent history" <a class="yt-timestamp" data-t="00:02:04">[00:02:04]</a>.

## Pharmaceutical Industry and Science

The private sector's role in scientific breakthroughs was highlighted during the pandemic. Companies produced respirators, treatments, and vaccines at unprecedented scales <a class="yt-timestamp" data-t="00:21:26">[00:21:26]</a>. The successful development of the Pfizer-BioNTech vaccine in record time showcased what is possible when science and industry work in tandem <a class="yt-timestamp" data-t="00:37:48">[00:37:48]</a>.

## Challenges and Misinformation

Despite these successes, public trust remains fragile, complicated by misinformation and skepticism. Bourla indicates that a small number of malicious actors exploit public fear and anxiety for profit, thus spreading division <a class="yt-timestamp" data-t="00:02:18">[00:02:18]</a>.

> [!info] Misinformation
> 
> "[A] small number of malicious people from all walks of life will use that fear and anger to divide us, because the division makes them money and gives them power" <a class="yt-timestamp" data-t="00:02:18">[00:02:18]</a>.

## Transparency and Ethical Challenges

One way to rebuild trust is through transparency, particularly in drug development and approval processes. Public figures and companies are often perceived with skepticism, requiring a commitment to transparency to mitigate doubts regarding [[transparency_and_regulation_in_drug_approval_processes | regulatory processes]] <a class="yt-timestamp" data-t="00:10:27">[00:10:27]</a>.

## Restoring Trust

Reputation is described as something "you can lose in buckets but you can earn it back in drops" <a class="yt-timestamp" data-t="00:20:27">[00:20:27]</a>. Bourla emphasizes that restoring trust requires consistent, ethical behavior and clear communication. The private sector's successes during the pandemic could help restore faith, but it requires ongoing efforts from companies to communicate openly and prioritize public welfare over profits <a class="yt-timestamp" data-t="00:21:26">[00:21:26]</a>.

In conclusion, pharmaceutical companies face significant hurdles in rebuilding public trust, exacerbated by historical grievances and ongoing controversies such as aggressive marketing practices and [[the_influence_of_the_pharmaceutical_industry_and_vaccine_safety | vaccine safety]]. However, the demonstrated value of science and technology during crises holds promise for the future relationship between these entities and the general populace.